Substituted indoles

Abstract

The present invention relates generally to substituted indoles and methods of using them.

1 . A compound having the formula:  
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or ester form thereof, wherein: 
 X is a bond or C 1 -C 6  alkylene;  
 R 1  and R 2  are, independently, hydrogen, C 1 -C 6  alkyl, C 2 -C 7  alkenyl, C 2 -C 7  alkynyl, C 3 -C 8  cycloalkyl, C 7 -C 11  bicycloalkyl, C 6 -C 10  aryl, heterocycle, —C(═O)C 1 -C 6  alkyl, —C(═O)aryl, —C(═O)heterocycle, —C(═O)N(R 6 )C 1 -C 6  alkyl, —C(═O)N(R 6 )aryl, —C(═O)N(R 6 )heterocycle, —SO 2 —C 1 -C 6  alkyl, —SO 2 -aryl, or —SO 2 -heterocycle;  
 or R 1  and R 2  together with the nitrogen to which they are attached form a heterocycle;  
 R 3  and R 4  are independently, hydrogen, halogen, C 1 -C 6  alkyl, C 1 -C 3  perfluoroalkyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyl, —C(═O)C 1 -C 3  alkyl, —OH, —NH 2 , or —NO 2 ;  
 R 5  is hydrogen, C 1 -C 6  alkyl, C 2 -C 7  alkenyl, C 2 -C 7  alkynyl, C 3 -C 8  cycloalkyl, C 7 -C 11  bicycloalkyl, C 6 -C 10  aryl, or heterocycle;  
 A is hydrogen, C 6 -C 10  aryl, or heterocycle; and  
 R 6  is hydrogen, C 1 -C 6  alkyl, halogen, C 2 -C 7  alkenyl, C 2 -C 7  alkynyl, C 3 -C 8  cycloalkyl, aralkyl, C 6 -C 10  aryl, heterocycle, hydroxy, C 1 -C 6  alkoxy, aryl-oxy, —CN, —C(═O)H, —CO 2 H, —OCO 2 C 1 -C 6  alkyl, —CO 2 C 1 -C 6  alkyl, —CO 2 -aryl, —CO 2 (C 1 -C 6  alkyl)aryl, —OCO 2 -aryl, —C(═O)NH 2 , —C(═O)NHOH, amino, C 1 -C 6  alkylamino, dialkylamino of 1-6 carbons per alkyl moiety, —NHC(═O)NH—C 1 -C 6  alkyl, —NHSO 2 —C 1 -C 6  alkyl, —NHSO 2 -aryl, or —NHSO 2 -heterocycle;  
 and wherein each of said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl and heterocycle groups being optionally substituted by one, two, three or more substituents.  
 
   
   
       2 . A compound of  claim 1 , having the formula:  
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt of ester form thereof,  
     wherein Y is NHSO 2 —C 1 -C 6  alkyl, NHSO 2 -aryl, NHSO 2 -heterocycle, pyrrole, NH-aryl, or NH-heterocycle.  
   
   
       3 . A compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof, wherein R 1  and R 2  are, independently, hydrogen, unsubstituted C 1 -C 6  alkyl, C 2 -C 7  alkenyl, C 2 -C 7  alkynyl, C 3 -C 8  cycloalkyl, C 7 -C 11  bicycloalkyl, C 6 -C 10  aryl, heterocyle, —C(═O)C 1 -C 6  alkyl, —C(═O)aryl, —C(═O)heterocycle, —C(═O)N(R 6 )C 1 -C 6  alkyl, —C(═O)N(R 6 )aryl, —C(═O)N(R 6 )heterocycle, —SO 2 —C 1 -C 6  alkyl, —SO 2 -aryl, or —SO 2 -heterocycle.  
   
   
       4 . A compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof, wherein R 1  and R 2  are, independently, hydrogen, unsubstituted SO 2 -alkyl, unsubstituted SO 2 -aryl, or SO 2 -aryl optionally substituted with —OCF 3 , aryl or alkyl.  
   
   
       5 . A compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof, wherein R 1  and R 2  together with the nitrogen form a heterocycle.  
   
   
       6 . A compound of  claim 5 , or a pharmaceutically acceptable salt or ester form thereof, wherein R 1  and R 2  together with the nitrogen form a pyrrole optionally substituted with one or two C 1 -C 6  alkyl groups.  
   
   
       7 . A compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof, wherein R 3  and R 4  are, independently, hydrogen, halogen, C 1 -C 3  perfluoroalkyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyl, —C(═O)C 1 -C 3  alkyl, —OH, —NH 2 , —NO 2 , unsubstituted C 1 -C 6  alkyl or C 1 -C 6  alkyl substituted with halogen, —CN, or alkoxy.  
   
   
       8 . A compound of  claim 1  wherein R 5  is hydrogen.  
   
   
       9 . A compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof, wherein A is hydrogen, phenyl, or thiophene.  
   
   
       10 . A compound of  claim 1  that is one of the following: 
 1-[4-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)phenyl]-H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-[4-(1H-pyrrol-1-yl)phenyl]-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-{4-[(1,1′-biphenyl-4-ylsulfonyl)amino]benzyl}-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-(4-{[(4-tert-butylphenyl)sulfonyl]amino}benzyl)-1H-indole-5-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof    or    1-{4-[(1,1′-biphenyl-4-ylsulfonyl)amino]benzyl}1H-indole-5-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof.    
   
   
       11 . A compound of  claim 1  that is that is one of the following: 
 1-(4-{[(4-tert-butylphenyl)sulfonyl]amino}benzyl)-1H-indole-3-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-{4-[(1,1′-biphenyl-4-ylsulfonyl)amino]benzyl}-1H-indole-3-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-(4-{[(4-tert-butylphenyl)sulfonyl]amino}benzyl)-1H-indole-4-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-{4-[(1,1′-biphenyl-4-ylsulfonyl)amino]benzyl}-1H-indole-4-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof    or    1-{4-[(1,1′-biphenyl-4-ylsulfonyl)amino]benzyl}-1H-indole-6-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof.    
   
   
       12 . A compound of  claim 1  that is one of the following: 
 3-phenyl-1-{4-[(phenylsulfonyl)amino]benzyl}-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof; 1-{4-[(methylsulfonyl)amino]benzyl}-3-phenyl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-{4-[(phenylsulfonyl)amino]benzyl}-3-thien-2-yl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof;    1-{4-[(methylsulfonyl)amino]benzyl}-3-thien-2-yl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof    or    1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)benzyl]-3-phenyl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof.    
   
   
       13 . A compound of  claim 1  that is 1-(4-anilinobenzyl)-3-phenyl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof.  
   
   
       14 . A compound of  claim 1  that is 1-(4-anilinobenzyl)-3-thien-2-yl-1H-indole-2-carboxylic acid or a pharmaceutically acceptable salt or ester form thereof.  
   
   
       15 . A method of inhibiting PAI-1 activity comprising administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof.  
   
   
       16 . A method for treating a PAI-1 related disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt or ester form thereof.  
   
   
       17 . The method of  claim 16 , wherein the PAI-1 related disorder is impairment of the fibrinolytic system.  
   
   
       18 . The method of  claim 16 , wherein the PAI-1 related disorder is thrombosis, atrial fibrillation, pulmonary fibrosis, myocardial ischemia, stroke, thromboembolic complication of surgery, cardiovascular disease, atherosclerotic plaque formation, chronic obstructive pulmonary disease, renal fibrosis, polycystic ovary syndrome, diabetes, Alzheimer's disease, or cancer.  
   
   
       19 . The method of  claim 18 , wherein the thrombosis is selected from the group consisting of venous thrombosis, arterial thrombosis, cerebral thrombosis, and deep vein thrombosis.  
   
   
       20 . The method of  claim 18 , wherein the PAI-1 related disorder is cardiovascular disease caused by noninsulin dependent diabetes mellitus in a subject.